202 related articles for article (PubMed ID: 11745491)
1. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.
Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ
Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
Lewis JS; Lewis MR; Cutler PD; Srinivasan A; Schmidt MA; Schwarz SW; Morris MM; Miller JP; Anderson CJ
Clin Cancer Res; 1999 Nov; 5(11):3608-16. PubMed ID: 10589778
[TBL] [Abstract][Full Text] [Related]
3. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
Lewis JS; Laforest R; Lewis MR; Anderson CJ
Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
[TBL] [Abstract][Full Text] [Related]
4. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
[TBL] [Abstract][Full Text] [Related]
8. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
11. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
13. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.
Anderson CJ; Jones LA; Bass LA; Sherman EL; McCarthy DW; Cutler PD; Lanahan MV; Cristel ME; Lewis JS; Schwarz SW
J Nucl Med; 1998 Nov; 39(11):1944-51. PubMed ID: 9829587
[TBL] [Abstract][Full Text] [Related]
14. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
Rolleman EJ; Krenning EP; Bernard BF; de Visser M; Bijster M; Visser TJ; Vermeij M; Lindemans J; de Jong M
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):219-27. PubMed ID: 17021812
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
17. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
Müller C; Forrer F; Bernard BF; Melis M; Konijnenberg M; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Feb; 22(1):151-9. PubMed ID: 17627424
[TBL] [Abstract][Full Text] [Related]
19. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
